New posts

Reply to thread

Message

AGM

Y23 CURVEBEAM AI HIGHLIGHTS
AGM PRESENTATION
• StraxCorp and CurveBeam merger completed in Q1 FY23
• Pre-IPO round closed Q3 FY23 – raised $25m
• The pre-IPO round showed a number of new institutional investors join our register.
• Listed on ASX - raised A$25m in August 2023 – (ASX: CVB)
• FY23 proforma revenue A$11.48m, circa 55% growth on FY22
• Foot & Ankle division of Stryker continues to build a strong prospects pipeline
• Primary company focus for FY24 is to place HiRise™ as quickly as possible –especially in the US market and to launch BMD SaaS model once FDA clearance is achieved.

forward, onward
• Deploying IPO capital to support HiRise™ placements for the rest of FY24
• The company focus remains
1. Driving growth in HiRise™ placements – especially in the US
2. Enhanced HiRise™ platform, especially for PSI & BMD functionality
3. Target launch for BMD SaaS business by the end of FY25
• FY24 orders – Company remains optimistic regarding the outlook for Stryker driven placements and sales. Timing of when sales are closed & booked remains outside the Company’s control
• Advancing enhanced HiRise™ platform for robotic system datasets to target
• Accelerating orders – Robotic Hip & Knee users in a group practice need validation from Stryker that HiRise™ can be used for other robotic datasets
• Improve diagnostic information for conditions identification around the hip & Knee
• US FDA filing bone mineral density (BMD) SaaS module – FDA clearance remains on late FY25 target

<blockquote data-quote="Dona Ferentes" data-source="post: 1253433" data-attributes="member: 66457">AGMY23 CURVEBEAM AI HIGHLIGHTS AGM PRESENTATION• StraxCorp and CurveBeam merger completed in Q1 FY23• Pre-IPO round closed Q3 FY23 – raised $25m • The pre-IPO round showed a number of new institutional investors join our register.• Listed on ASX - raised A$25m in August 2023 – (ASX: CVB)• FY23 proforma revenue A$11.48m, circa 55% growth on FY22• Foot &amp; Ankle division of Stryker continues to build a strong prospects pipeline• Primary company focus for FY24 is to place HiRise™ as quickly as possible –especially in the US market and to launch BMD SaaS model once FDA clearance is achieved.forward, onward• Deploying IPO capital to support HiRise™ placements for the rest of FY24• The company focus remains1. Driving growth in HiRise™ placements – especially in the US2. Enhanced HiRise™ platform, especially for PSI &amp; BMD functionality3. Target launch for BMD SaaS business by the end of FY25• FY24 orders – Company remains optimistic regarding the outlook for Stryker driven placements and sales. Timing of when sales are closed &amp; booked remains outside the Company’s control• Advancing enhanced HiRise™ platform for robotic system datasets to target• Accelerating orders – Robotic Hip &amp; Knee users in a group practice need validation from Stryker that HiRise™ can be used for other robotic datasets• Improve diagnostic information for conditions identification around the hip &amp; Knee• US FDA filing bone mineral density (BMD) SaaS module – FDA clearance remains on late FY25 target</blockquote>

[QUOTE="Dona Ferentes, post: 1253433, member: 66457"] AGM [I][B][COLOR=rgb(0, 168, 133)]Y23 CURVEBEAM AI HIGHLIGHTS [/COLOR][/B][/I] [B][I][COLOR=rgb(0, 168, 133)]AGM PRESENTATION[/COLOR][/I][/B] • [COLOR=rgb(44, 130, 201)]StraxCorp and CurveBeam merger completed in Q1 FY23 • Pre-IPO round closed Q3 FY23 – raised $25m • The pre-IPO round showed a number of new institutional investors join our register. • Listed on ASX - raised A$25m in August 2023 – (ASX: CVB) • FY23 proforma revenue A$11.48m, circa 55% growth on FY22 • Foot & Ankle division of Stryker continues to build a strong prospects pipeline • Primary company focus for FY24 is to place HiRise™ as quickly as possible –especially in the US market and to launch BMD SaaS model once FDA clearance is achieved.[/COLOR] [COLOR=rgb(65, 168, 95)][B][I]forward, onward[/I][/B][/COLOR] • Deploying IPO capital to support HiRise™ placements for the rest of FY24 • The company focus remains 1. Driving growth in HiRise™ placements – especially in the US 2. Enhanced HiRise™ platform, especially for PSI & BMD functionality 3. Target launch for BMD SaaS business by the end of FY25 • FY24 orders – Company remains optimistic regarding the outlook for Stryker driven placements and sales. Timing of when sales are closed & booked remains outside the Company’s control • Advancing enhanced HiRise™ platform for robotic system datasets to target • Accelerating orders – Robotic Hip & Knee users in a group practice need validation from Stryker that HiRise™ can be used for other robotic datasets • Improve diagnostic information for conditions identification around the hip & Knee • US FDA filing bone mineral density (BMD) SaaS module – FDA clearance remains on late FY25 target [/QUOTE]

Verification